Who Buys Dapagliflozin from India — 502 Importers Behind a $49.5M Market

The 502 buyers of Dapagliflozin from India can be categorized into several segments:

• Distributors: Entities like GROUPE AFFI (Canada) and JAMP PHARMA CORPORATION (Canada) function as intermediaries, purchasing Dapagliflozin in bulk and supplying it to pharmacies, hospitals, and clinics. Their buying behavior typically involves large, regular orders to maintain a steady supply chain.

• Contract Manufacturers: Companies such as MYLAN IRELAND LTD (Netherlands) and AURO PHARMA INC (Canada) procure Dapagliflozin as an active pharmaceutical ingredient (API) for the production of finished dosage forms. Their procurement patterns are aligned with production schedules and market demand forecasts.

• Re-exporters: Firms like REGENCY PHARMA LIMITED (Mauritius) and JONAR TRANSPORT (Iceland) import Dapagliflozin with the intent to export it to other markets. Their purchasing behavior is influenced by global demand fluctuations and regulatory environments in target export destinations.

• Government Procurement Agencies: Entities such as AWAMEDICA (Iraq) and AWAMEDICA PESHAWA STREET (Iraq) likely engage in procurement for public health initiatives, including national tenders. Their buying patterns are characterized by large-volume purchases, often through competitive bidding processes, to meet public health needs.

Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and behaviors of each buyer type.

For the top five importing countries, the import regulations for Dapagliflozin are as follows:

• Canada:
• Regulatory Authority: Health Canada.
• Import Registration Process: Importers must obtain a Drug Establishment License (DEL) and ensure the product is listed on Health Canada's Drug Product Database. Exceptional importation is permitted under specific conditions, such as drug shortages, as outlined in the Food and Drug Regulations.
• Estimated Timeline for Registration: The standard review process for a New Drug Submission (NDS) is approximately 300 days.
• Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are typically duty-free in Canada.

• Iraq:
• Regulatory Authority: Ministry of Health, Iraq.
• Import Registration Process: Importers must register pharmaceutical products with the State Company for Marketing Drugs and Medical Appliances (Kimadia), providing comprehensive documentation including product dossiers and certificates of analysis.
• Estimated Timeline for Registration: The registration process can take between 6 to 12 months, depending on the completeness of the application and regulatory workload.
• Import Tariff/Duty for HS 30049099: Pharmaceutical imports are generally subject to a 5% customs duty, though exemptions may apply for essential medicines.

• China:
• Regulatory Authority: National Medical Products Administration (NMPA).
• Import Registration Process: Foreign manufacturers must obtain a Drug Import License and register the product with the NMPA, which includes submitting clinical trial data and undergoing a Good Manufacturing Practice (GMP) inspection.
• Estimated Timeline for Registration: The process typically takes 12 to 18 months.
• Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are subject to a 4% import duty, with potential reductions under specific trade agreements.

• Netherlands:
• Regulatory Authority: Medicines Evaluation Board (MEB).
• Import Registration Process: Importers must ensure the product has a valid marketing authorization from the MEB. Mutual recognition procedures within the EU can expedite this process if the product is already authorized in another EU member state.
• Estimated Timeline for Registration: Approximately 210 days under the decentralized procedure.
• Import Tariff/Duty for HS 30049099: As part of the EU, the Netherlands applies a 0% import duty on pharmaceutical products under this HS code.

• Philippines:
• Regulatory Authority: Food and Drug Administration Philippines (FDA Philippines).
• Import Registration Process: Importers must secure a Certificate of Product Registration (CPR) from the FDA Philippines, which involves submitting product dossiers, GMP certificates, and samples for evaluation.
• Estimated Timeline for Registration: The registration process can take 6 to 12 months.
• Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are generally subject to a 3% import duty, with possible exemptions for essential medicines.

Compliance with these regulations is essential for market entry and sustained operations in these countries.

The demand for Dapagliflozin in importing countries is driven by several factors:

• Disease Prevalence: The rising incidence of type 2 diabetes globally has increased the need for effective treatments like Dapagliflozin. For instance, the International Diabetes Federation reported in 2025 that approximately 537 million adults worldwide were living with diabetes, a significant increase from previous years.

• Government Healthcare Programs: Many countries have implemented national health programs aimed at managing chronic diseases, including diabetes. These programs often subsidize medications, making them more accessible to the population.

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased inclusion of essential medicines in national formularies, thereby boosting demand.

• WHO Essential Medicines List Procurement: Inclusion of Dapagliflozin in the WHO Essential Medicines List encourages countries to procure it for their public health systems, ensuring wider availability.

• Tender-Based Purchasing: Government and large healthcare providers often use tendering processes to procure medications, leading to bulk purchases and stable demand.

With 502 buyers across 113 countries, the market for Dapagliflozin is robust, reflecting its critical role in diabetes management and the global commitment to improving healthcare outcomes.

The 502 buyers of Dapagliflozin from India can be categorized into several segments:

• Distributors: Entities like GROUPE AFFI (Canada) and JAMP PHARMA CORPORATION (Canada) function as intermediaries, purchasing Dapagliflozin in bulk and supplying it to pharmacies, hospitals, and clinics. Their buying behavior typically involves large, regular orders to maintain a steady supply chain.

• Contract Manufacturers: Companies such as MYLAN IRELAND LTD (Netherlands) and AURO PHARMA INC (Canada) procure Dapagliflozin as an active pharmaceutical ingredient (API) for the production of finished dosage forms. Their procurement patterns are aligned with production schedules and market demand forecasts.

• Re-exporters: Firms like REGENCY PHARMA LIMITED (Mauritius) and JONAR TRANSPORT (Iceland) import Dapagliflozin with the intent to export it to other markets. Their purchasing behavior is influenced by global demand fluctuations and regulatory environments in target export destinations.

• Government Procurement Agencies: Entities such as AWAMEDICA (Iraq) and AWAMEDICA PESHAWA STREET (Iraq) likely engage in procurement for public health initiatives, including national tenders. Their buying patterns are characterized by large-volume purchases, often through competitive bidding processes, to meet public health needs.

Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and behaviors of each buyer type.

For the top five importing countries, the import regulations for Dapagliflozin are as follows:

• Canada:
• Regulatory Authority: Health Canada.
• Import Registration Process: Importers must obtain a Drug Establishment License (DEL) and ensure the product is listed on Health Canada's Drug Product Database. Exceptional importation is permitted under specific conditions, such as drug shortages, as outlined in the Food and Drug Regulations.
• Estimated Timeline for Registration: The standard review process for a New Drug Submission (NDS) is approximately 300 days.
• Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are typically duty-free in Canada.

• Iraq:
• Regulatory Authority: Ministry of Health, Iraq.
• Import Registration Process: Importers must register pharmaceutical products with the State Company for Marketing Drugs and Medical Appliances (Kimadia), providing comprehensive documentation including product dossiers and certificates of analysis.
• Estimated Timeline for Registration: The registration process can take between 6 to 12 months, depending on the completeness of the application and regulatory workload.
• Import Tariff/Duty for HS 30049099: Pharmaceutical imports are generally subject to a 5% customs duty, though exemptions may apply for essential medicines.

• China:
• Regulatory Authority: National Medical Products Administration (NMPA).
• Import Registration Process: Foreign manufacturers must obtain a Drug Import License and register the product with the NMPA, which includes submitting clinical trial data and undergoing a Good Manufacturing Practice (GMP) inspection.
• Estimated Timeline for Registration: The process typically takes 12 to 18 months.
• Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are subject to a 4% import duty, with potential reductions under specific trade agreements.

• Netherlands:
• Regulatory Authority: Medicines Evaluation Board (MEB).
• Import Registration Process: Importers must ensure the product has a valid marketing authorization from the MEB. Mutual recognition procedures within the EU can expedite this process if the product is already authorized in another EU member state.
• Estimated Timeline for Registration: Approximately 210 days under the decentralized procedure.
• Import Tariff/Duty for HS 30049099: As part of the EU, the Netherlands applies a 0% import duty on pharmaceutical products under this HS code.

• Philippines:
• Regulatory Authority: Food and Drug Administration Philippines (FDA Philippines).
• Import Registration Process: Importers must secure a Certificate of Product Registration (CPR) from the FDA Philippines, which involves submitting product dossiers, GMP certificates, and samples for evaluation.
• Estimated Timeline for Registration: The registration process can take 6 to 12 months.
• Import Tariff/Duty for HS 30049099: Pharmaceutical products under this HS code are generally subject to a 3% import duty, with possible exemptions for essential medicines.

Compliance with these regulations is essential for market entry and sustained operations in these countries.

The demand for Dapagliflozin in importing countries is driven by several factors:

• Disease Prevalence: The rising incidence of type 2 diabetes globally has increased the need for effective treatments like Dapagliflozin. For instance, the International Diabetes Federation reported in 2025 that approximately 537 million adults worldwide were living with diabetes, a significant increase from previous years.

• Government Healthcare Programs: Many countries have implemented national health programs aimed at managing chronic diseases, including diabetes. These programs often subsidize medications, making them more accessible to the population.

• Universal Health Coverage Expansion: Efforts to achieve universal health coverage have led to increased inclusion of essential medicines in national formularies, thereby boosting demand.

• WHO Essential Medicines List Procurement: Inclusion of Dapagliflozin in the WHO Essential Medicines List encourages countries to procure it for their public health systems, ensuring wider availability.

• Tender-Based Purchasing: Government and large healthcare providers often use tendering processes to procure medications, leading to bulk purchases and stable demand.

With 502 buyers across 113 countries, the market for Dapagliflozin is robust, reflecting its critical role in diabetes management and the global commitment to improving healthcare outcomes.